Biomedical Science and Research Journals | Future of Biotech Equipment/Medical Device Research & Development: A Case for Redemption of the Neglect

 

Future of Biotech Equipment/Medical Device Research & Development: A Case for Redemption of the Neglect

Introduction

The global healthcare industry is undergoing a progressive transformation at a rapid pace. Ground breaking innovation across multiple fields including biotechnology, pharmaceutical and medical devices is driving this transformative journey, the main outcome of which is improved patient health and decreased cost burden resulting in enhanced quality of life.

Small molecule drug development and advances in bio therapeutic formulations by various pharmaceutical and biotechnological companies respectively, either alone, or in collaboration with dedicated research groups in academia tend to garner the majority of government and non-governmental funding. However, a critical area of biomedical research that lags behind in comparison with its peers in this category are biomedical devices that are also an integral part of patient therapy. While this disparity is most evident in the developing countries beset with social inequalities and a lack of medical infrastructure [1] , even in developed nations leading in biotech innovation such as the US there has been a steady decline in the investment poured into this field with a fall in available funding from 11% in 2010 to approximately 5% in 2016 [2] . Collectively, this imbalance could perhaps be applied to the term “10/90 Gap” coined by Global Forum for Health Research [3] to reflect that only 10% of health research funds are spent on the problem of developing optimum biotech equipment and devices for 90% of the world’s population.

Traditionally, most of the research and development (R&D) of new and efficient biotech equipment especially smaller medical devices are undertaken by startup companies which invariably depend on funding provided by private equity/venture capitalists. But the risks associated with market stability coupled with slow pace of development including the prolonged process of getting FDA approval oftentimes result in the redirection of finances from these sources towards more lucrative non-medtech sectors wherein the time gap from development to actualization of return is less. The big players, namely the corporate sharks on the other hand are more prone to withhold investing in smaller startups and rather play a wait and watch approach to let the completion of the development and testing process before paying to acquire the business in its entirety.

Despite these setbacks the tides are starting to turn in favor of greater opportunities for those involved in R&D in the biotech equipment/medical device sector at both the industry and academic levels. The potential for crowd sourcing funds to support startups and establishment of grants to sponsor seed money by Research Institutions is a step in the right direction. It is indeed heartening to note that in the 2018 cycle of the LEAP Inventor Challenge Awards administered by the Skandalaris Center for Interdisciplinary Innovation & Entrepreneurship at the Washington University in St Louis, 3 out of the 5 awards conferred were in the area of medical device development. As the transformative journey in this previously eclipsed field gathers renewed momentum the hope for further advancements in the future holds promise.

For More information: https://biomedgrid.com/fulltext/volume7/future-of-biotech-equipment-medical-device-research-development.001134.php

Know More Information: Biomed Grid Please Click on : https://biomedgrid.com

For More information: Open Access Journals of Biomedical Science and ResearchJournal of Biomedical Science 

Know More Information: Biomed Grid Please Click on : https://biomedgrid.com

Comments

Popular posts from this blog

Biomedical Science and Research Journals | Advanced Applications of Biomaterials Based on Alginic Acid

Biomedical Science and Research Journals | Banking Progenitor Cells for Hippiatric Regenerative Medicine: Optimized Establishment of Safe and Consistent Cell Sources for Standardized Veterinary Therapeutic Protocols